Get the Stockscreener App
0.1256
19.62%
0.0206
After Hours:
.13
0.0044
+3.50%
Aspire Biopharma Holdings Inc stock is traded at $0.1256, with a volume of 504.16M.
It is up +19.62% in the last 24 hours and up +37.27% over the past month.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.
See More
Previous Close:
$0.105
Open:
$0.16445
24h Volume:
504.16M
Relative Volume:
14.53
Market Cap:
$17.39M
Revenue:
-
Net Income/Loss:
$-27.39M
P/E Ratio:
-0.0747
EPS:
-1.6803
Net Cash Flow:
$-2.09M
1W Performance:
-4.78%
1M Performance:
+37.27%
6M Performance:
-56.07%
1Y Performance:
+0.00%
1-Day Range:
$0.1249
$0.171
1-Week Range:
$0.1004
$0.171
52-Week Range:
$0.0709
$2.10
Aspire Biopharma Holdings Inc Stock (ASBP) Company Profile
Name
Aspire Biopharma Holdings Inc
Sector
Industry
Phone
561-704-8527
Address
23150 FASHION DRIVE, SUITE 232, ESTERO
Compare ASBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ASBP
Aspire Biopharma Holdings Inc
|
0.1256 | 14.54M | 0 | -27.39M | -2.09M | -1.6803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aspire Biopharma Holdings Inc Stock (ASBP) Latest News
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
ASBP Stock Soars 32% After Favorable Feedback From FDA For Its Aspirin – Retail Expects Licensing Negotiations Soon - Stocktwits
Aspire Biopharma stock soars after FDA meeting clears path for heart attack drug By Investing.com - Investing.com South Africa
Aspire Biopharma stock soars after FDA meeting clears path for heart attack drug - Investing.com Canada
FDA feedback clears path for Aspire Biopharma’s heart attack drug - Investing.com India
FDA feedback clears path for Aspire Biopharma’s heart attack drug By Investing.com - Investing.com Australia
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA) - ACCESS Newswire
FDA backs trial of faster-acting aspirin powder for heart attacks - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Aspire Biopharma Restructures Debt via Equity Exchange Agreements - TipRanks
Aspire Biopharma Holdings Signs Debt-for-Equity Exchange Agreements With Certain Debt Holders - TradingView — Track All Markets
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements - Asbury Park Press
Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - The Coloradoan
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Aspire Biopharma Provides Q3 2025 Business Update - Montgomery Advertiser
Aspire Biopharma Holdings, Inc. Announces CEO Transition - aberdeennews.com
Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member - Petoskey News-Review
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - Pensacola News Journal
Aspire Biopharma Holdings, Inc. Warrant 2025-18.02.30 on Aspire Bio Hldgs Revenue Breakdown – NASDAQ:ASBPW - TradingView — Track All Markets
Aspire Biopharma Holdings, Inc. Warrant 2025-18.02.30 on Aspire Bio Hldgs - TradingView — Track All Markets
Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin - Bluffton Today
Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine - The Florida Times-Union
ASBPAI Stock Analysis - Meyka
Aspire Biopharma welcomes Ashley Paulson as Brand Ambassador - Comunicaffe International
Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Gl - The National Law Review
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Aspire Biopharma names Ashley Paulson BUZZ BOMB global brand ambassador - TipRanks
Aspire Biopharma Holdings (ASBP) Stock on Dec. 15, 2025: Nasdaq Extension, FDA Pre‑IND Momentum, and Dilution Risks Investors Are Watching - ts2.tech
Aspire Biopharma Holdings Inc Stock (ASBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
28.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):